AU2017281928B2 - Method and process for quantitative evaluation of pharmacokinetics, therapeutic effects and safety of delivery of drug compounds to the inner ear for treatment of auditory diseases - Google Patents

Method and process for quantitative evaluation of pharmacokinetics, therapeutic effects and safety of delivery of drug compounds to the inner ear for treatment of auditory diseases Download PDF

Info

Publication number
AU2017281928B2
AU2017281928B2 AU2017281928A AU2017281928A AU2017281928B2 AU 2017281928 B2 AU2017281928 B2 AU 2017281928B2 AU 2017281928 A AU2017281928 A AU 2017281928A AU 2017281928 A AU2017281928 A AU 2017281928A AU 2017281928 B2 AU2017281928 B2 AU 2017281928B2
Authority
AU
Australia
Prior art keywords
pack composition
peg
mol
subject
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017281928A
Other languages
English (en)
Other versions
AU2017281928A1 (en
Inventor
Andrew AYOOB
Jeffrey T. Borenstein
Ernest S. Kim
Robert Langer
Michael Mckenna
Erin PARARAS
Marcello PEPPI
William SEWELL
Vishal Tandon
Marc Weinberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Charles Stark Draper Laboratory Inc
Massachusetts Institute of Technology
Massachusetts Eye and Ear
Original Assignee
Charles Stark Draper Laboratory Inc
Massachusetts Eye and Ear Infirmary
Massachusetts Institute of Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Charles Stark Draper Laboratory Inc, Massachusetts Eye and Ear Infirmary, Massachusetts Institute of Technology filed Critical Charles Stark Draper Laboratory Inc
Publication of AU2017281928A1 publication Critical patent/AU2017281928A1/en
Application granted granted Critical
Publication of AU2017281928B2 publication Critical patent/AU2017281928B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0046—Ear
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2017281928A 2016-06-23 2017-06-23 Method and process for quantitative evaluation of pharmacokinetics, therapeutic effects and safety of delivery of drug compounds to the inner ear for treatment of auditory diseases Active AU2017281928B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662353676P 2016-06-23 2016-06-23
US62/353,676 2016-06-23
PCT/US2017/039090 WO2017223498A1 (en) 2016-06-23 2017-06-23 Method and process for quantitative evaluation of pharmacokinetics, therapeutic effects and safety of delivery of drug compounds to the inner ear for treatment of auditory diseases

Publications (2)

Publication Number Publication Date
AU2017281928A1 AU2017281928A1 (en) 2019-02-07
AU2017281928B2 true AU2017281928B2 (en) 2023-04-13

Family

ID=59297388

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017281928A Active AU2017281928B2 (en) 2016-06-23 2017-06-23 Method and process for quantitative evaluation of pharmacokinetics, therapeutic effects and safety of delivery of drug compounds to the inner ear for treatment of auditory diseases

Country Status (5)

Country Link
US (1) US10596267B2 (https=)
EP (1) EP3474852A1 (https=)
JP (1) JP2019524672A (https=)
AU (1) AU2017281928B2 (https=)
WO (1) WO2017223498A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020254249A1 (en) 2019-06-21 2020-12-24 Proqr Therapeutics Ii B.V. Delivery of nucleic acids for the treatment of auditory disorders
MX2022013897A (es) * 2020-05-06 2023-02-09 Regeneron Pharma Dominio kelch que contiene variantes de 7b (klhdc7b) y usos de estas.

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100015263A1 (en) * 2008-07-21 2010-01-21 Otonomy, Inc. Controlled release auris sensory cell modulator compositions and methods for the treatment of otic disorders
US20130085476A1 (en) * 2011-09-26 2013-04-04 InClube Labs, LLC System and method for delivery of a therapeutic agent to the inner ear
US20140200395A1 (en) * 2012-12-11 2014-07-17 Bilal Shafi Apparatuses and methods for preventing or reversing heart dilation

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8099156B1 (en) * 2006-09-15 2012-01-17 The Board Of Trustees Of The Leland Stanford Junior University Cochlear optical analysis system and approach therefor
US8883185B2 (en) * 2010-05-27 2014-11-11 Covidien Lp Hydrogel implants with varying degrees of crosslinking

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100015263A1 (en) * 2008-07-21 2010-01-21 Otonomy, Inc. Controlled release auris sensory cell modulator compositions and methods for the treatment of otic disorders
US20130085476A1 (en) * 2011-09-26 2013-04-04 InClube Labs, LLC System and method for delivery of a therapeutic agent to the inner ear
US20140200395A1 (en) * 2012-12-11 2014-07-17 Bilal Shafi Apparatuses and methods for preventing or reversing heart dilation

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
EL KECHAI NAILA ET AL: "Recent advances in local drug delivery to the inner ear", INTERNATIONAL JOURNAL OF PHARMACEUTICS, vol. 494, no. 1, 7 August 2015 (2015-08-07), pages 83 - 101 *
Hutten et al. (PLOS One, Aug. 2014, vol. 9, pp. 1-13) (Year: 2014). *
Liang, Y., et al., 'Controlled release of an anthrax toxin-neutralizing antibody from hydrolytically degradable polyethylene glycol hydrogels'. Journal of biomedical materials research. Part A, (January 2016), vol. 104, no. 1, p 113–123. *
Ortal Yom-Tov, et al., 'PEG-Thiol based hydrogels with controllable properties', European Polymer Journal, (January 2016), Vol. 74, Pages 1-12, *
YU DEHONG ET AL: "Inner ear delivery of dexamethasone using injectable silk-polyethylene glycol (PEG) hydrogel", INTERNATIONAL JOURNAL OF PHARMACEUTICS, ELSEVIER, AMSTERDAM, NL, vol. 503, no. 1, 10 March 2016 (2016-03-10), pages 229 - 237 *
YU JING ET AL: "In situ covalently cross-linked PEG hydrogel for ocular drug delivery applications", INTERNATIONAL JOURNAL OF PHARMACEUTICS, vol. 470, no. 1, 23 April 2014 (2014-04-23), pages 151 - 157 *

Also Published As

Publication number Publication date
EP3474852A1 (en) 2019-05-01
US20180000956A1 (en) 2018-01-04
JP2019524672A (ja) 2019-09-05
WO2017223498A1 (en) 2017-12-28
US10596267B2 (en) 2020-03-24
AU2017281928A1 (en) 2019-02-07
CA3029319A1 (en) 2017-12-28

Similar Documents

Publication Publication Date Title
Hao et al. Inner ear drug delivery: recent advances, challenges, and perspective
Salt et al. Principles of local drug delivery to the inner ear
Liu et al. Current strategies for drug delivery to the inner ear
Salt et al. Local inner-ear drug delivery and pharmacokinetics
Rivera et al. Drug delivery to the inner ear: strategies and their therapeutic implications for sensorineural hearing loss
CA2620374C (en) Pharmaceutical compositions for the treatment of inner ear disorders
Paulson et al. A novel controlled local drug delivery system for inner ear disease
Agban et al. Depot formulations to sustain periocular drug delivery to the posterior eye segment
Ayoob et al. The role of intracochlear drug delivery devices in the management of inner ear disease
US20260041897A1 (en) Targeted drug delivery methods using a microneedle
Honeder et al. Sustained release of triamcinolone acetonide from an intratympanically applied hydrogel designed for the delivery of high glucocorticoid doses
US20180360743A1 (en) Thermoresponsive polymers and uses thereof
WO1997038698A1 (en) Methods for treating middle and inner ear disorders
AU2017281928B2 (en) Method and process for quantitative evaluation of pharmacokinetics, therapeutic effects and safety of delivery of drug compounds to the inner ear for treatment of auditory diseases
Pierstorff et al. A polymer-based extended release system for stable, long-term intracochlear drug delivery
CA3029319C (en) Method and process for quantitative evaluation of pharmacokinetics, therapeutic effects and safety of delivery of drug compounds to the inner ear for treatment of auditory diseases
Ji et al. Liposome Encapsulation Enhances Ripasudil Therapeutic Efficacy Against Proliferative Vitreoretinal Diseases: Implications in Advanced Ocular Treatment
Neamah et al. Intravitreal implantable film containing ketorolac tromethamine microsponges in vitro/in vivo correlation
Bruk Development of a Novel Topical Controlled Release System for Otic Drug Delivery
AR et al. Ophthalmic Liquid Crystal In-Situ Gel Formulation and Evaluation–Insight from a Systematic Literature Review
Mehta et al. Intravitreal Injection Drug Delivery for
Vettori A Summary of the Advances in Ophthalmic Drug Delivery via Iontophoresis and Microneedles
Nguyen et al. Recent advances in therapeutics and drug delivery for the treatment of inner ear diseases: a patent
Plontke Drug Delivery: Inner Ear
Gao et al. In Situ Temperature-Sensitive Hydrogel for Ophthalmic Administration, Using Pilocarpine Nitrate as a Case Study

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)